Clinical profile of patients with MDS with thrombocytopenia
| Feature . | Isolated thrombocytopenia (n = 191) . | Bicytopenia (n = 389) . | Pancytopenia (n = 530) . | P . |
|---|---|---|---|---|
| Age at diagnosis, y | 56 (37-68) | 57 (38.5-66) | 53 (38-63) | .056 |
| Sex | .137 | |||
| Female | 95 (49.7) | 162 (41.6) | 247 (46.6) | |
| Male | 96 (50.3) | 227 (58.4) | 283 (53.4) | |
| Cytopenias | ||||
| Hb, g/dL | 117 (108-131) | 94 (69-113) | 71 (58-84) | .000 |
| ANC, ×109/L | 3.0 (2.2-4.7) | 1.9 (1.2-3.2) | 0.9 (0.5-1.3) | .000 |
| Platelets, × 109/L | 46 (31-67) | 46 (25-70) | 35 (18-63) | .000 |
| Severe thrombocytopenia | 19 (9.9) | 64 (16.5) | 152 (28.7) | .000 |
| Moderate thrombocytopenia | 87 (45.5) | 144 (37.0) | 180 (34.0) | |
| Bone marrow blasts, % | 2.5 (1.0-5.0) | 4.0 (1.8-8.5) | 4.0 (1.2-10.5) | .000 |
| WHO classification | .000 | |||
| MDS-SLD | 26 (13.6) | 59 (15.2) | 82 (15.5) | |
| MDS-MLD | 9 (4.7) | 25 (6.4) | 23 (4.3) | |
| MDS-RS | 2 (1.0) | 5 (1.3) | 6 (1.1) | |
| 5q- | 0 | 0 | 1 (0.2) | |
| MDS-EB-1 | 44 (23.0) | 108 (27.8) | 103 (19.4) | |
| MDS-EB-2 | 19 (9.9) | 84 (21.6) | 149 (28.1) | |
| MDS-U | 91 (47.6) | 108 (27.8) | 166 (31.3) | |
| Cytogenetic risk | ||||
| Very good | 3 (1.6) | 8 (2.1) | 7 (1.3) | .037 |
| Good | 110 (57.6) | 227 (58.4) | 291 (54.9) | |
| Intermediate | 63 (33.0) | 103 (26.5) | 135 (25.5) | |
| Poor | 8 (4.2) | 19 (4.9) | 38 (7.2) | |
| Very poor | 7 (3.7) | 32 (8.2) | 59 (11.1) | |
| MK | 13 (6.8) | 61 (15.7) | 77 (14.5) | .014 |
| IPSS-R | ||||
| Very low | 25 (13.1) | 13 (3.3) | 0 (0.0) | .000 |
| Low | 85 (44.5) | 79 (20.3) | 49 (9.2) | |
| Intermediate | 32 (16.8) | 144 (37.0) | 170 (32.1) | |
| High | 34 (17.8) | 91 (23.4) | 138 (26.0) | |
| Very high | 15 (7.9) | 62 (15.9) | 173 (32.6) | |
| AML evolution | 24 (12.6) | 61 (15.7) | 121 (22.8) | .002 |
| Feature . | Isolated thrombocytopenia (n = 191) . | Bicytopenia (n = 389) . | Pancytopenia (n = 530) . | P . |
|---|---|---|---|---|
| Age at diagnosis, y | 56 (37-68) | 57 (38.5-66) | 53 (38-63) | .056 |
| Sex | .137 | |||
| Female | 95 (49.7) | 162 (41.6) | 247 (46.6) | |
| Male | 96 (50.3) | 227 (58.4) | 283 (53.4) | |
| Cytopenias | ||||
| Hb, g/dL | 117 (108-131) | 94 (69-113) | 71 (58-84) | .000 |
| ANC, ×109/L | 3.0 (2.2-4.7) | 1.9 (1.2-3.2) | 0.9 (0.5-1.3) | .000 |
| Platelets, × 109/L | 46 (31-67) | 46 (25-70) | 35 (18-63) | .000 |
| Severe thrombocytopenia | 19 (9.9) | 64 (16.5) | 152 (28.7) | .000 |
| Moderate thrombocytopenia | 87 (45.5) | 144 (37.0) | 180 (34.0) | |
| Bone marrow blasts, % | 2.5 (1.0-5.0) | 4.0 (1.8-8.5) | 4.0 (1.2-10.5) | .000 |
| WHO classification | .000 | |||
| MDS-SLD | 26 (13.6) | 59 (15.2) | 82 (15.5) | |
| MDS-MLD | 9 (4.7) | 25 (6.4) | 23 (4.3) | |
| MDS-RS | 2 (1.0) | 5 (1.3) | 6 (1.1) | |
| 5q- | 0 | 0 | 1 (0.2) | |
| MDS-EB-1 | 44 (23.0) | 108 (27.8) | 103 (19.4) | |
| MDS-EB-2 | 19 (9.9) | 84 (21.6) | 149 (28.1) | |
| MDS-U | 91 (47.6) | 108 (27.8) | 166 (31.3) | |
| Cytogenetic risk | ||||
| Very good | 3 (1.6) | 8 (2.1) | 7 (1.3) | .037 |
| Good | 110 (57.6) | 227 (58.4) | 291 (54.9) | |
| Intermediate | 63 (33.0) | 103 (26.5) | 135 (25.5) | |
| Poor | 8 (4.2) | 19 (4.9) | 38 (7.2) | |
| Very poor | 7 (3.7) | 32 (8.2) | 59 (11.1) | |
| MK | 13 (6.8) | 61 (15.7) | 77 (14.5) | .014 |
| IPSS-R | ||||
| Very low | 25 (13.1) | 13 (3.3) | 0 (0.0) | .000 |
| Low | 85 (44.5) | 79 (20.3) | 49 (9.2) | |
| Intermediate | 32 (16.8) | 144 (37.0) | 170 (32.1) | |
| High | 34 (17.8) | 91 (23.4) | 138 (26.0) | |
| Very high | 15 (7.9) | 62 (15.9) | 173 (32.6) | |
| AML evolution | 24 (12.6) | 61 (15.7) | 121 (22.8) | .002 |
Data are n (%) or median (interquartile range).
5q-, MDS with isolated del(5q); ANC, absolute neutrophil count; Hb, hemoglobin; IPSS-R, Revised International Prognostic Scoring System; MDS-EB, MDS with excess blasts; MDS-MLD, MDS with multilineage dysplasia; MDS-RS, MDS with ring sideroblasts; MDS-SLD, MDS with single-lineage dysplasia; MDS-U, MDS-unclassifiable; MK, monosomal karyotype; WBC, white blood cell.